182 related articles for article (PubMed ID: 31357080)
1. One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.
Liu Y; Yang N; Peng X; Liu G; Zhong H; Liu L
Biomed Pharmacother; 2019 Oct; 118():109254. PubMed ID: 31357080
[TBL] [Abstract][Full Text] [Related]
2. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
5. A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma.
Ren L; Xu B; Xu J; Li J; Jiang J; Ren Y; Liu P
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047654
[TBL] [Abstract][Full Text] [Related]
6. High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma.
Huang LJ; Shen Y; Bai J; Wang FX; Feng YD; Chen HL; Peng Y; Zhang R; Li FM; Zhang PH; Lei XR; Xue F; Ma YP; Hu JS; He AL
Acta Haematol; 2020; 143(3):279-288. PubMed ID: 31597158
[TBL] [Abstract][Full Text] [Related]
7. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
8. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D
Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658
[TBL] [Abstract][Full Text] [Related]
9. Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma.
Hu AX; Huang ZY; Zhang L; Shen J
Tumour Biol; 2017 Apr; 39(4):1010428317694563. PubMed ID: 28378636
[TBL] [Abstract][Full Text] [Related]
10. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
11. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
12. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.
Samur MK; Minvielle S; Gulla A; Fulciniti M; Cleynen A; Aktas Samur A; Szalat R; Shammas M; Magrangeas F; Tai YT; Auclair D; Keats J; Richardson P; Attal M; Moreau P; Anderson KC; Parmigiani G; Avet-Loiseau H; Munshi NC
Leukemia; 2018 Dec; 32(12):2626-2635. PubMed ID: 29749396
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
14. The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.
Lee YS; Heo W; Nam J; Jeung YH; Bae J
J Radiat Res; 2018 May; 59(3):245-252. PubMed ID: 29518205
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for predicting prognosis of multiple myeloma patients based on a ubiquitin-proteasome gene signature.
Ji D; Liu Y; Sun W; Shi Q; Chen G; Song Z; Jiang Y
Aging (Albany NY); 2022 Dec; 14(24):9951-9968. PubMed ID: 36534449
[TBL] [Abstract][Full Text] [Related]
16. Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.
Zamani-Ahmadmahmudi M; Nassiri SM; Soltaninezhad F
Br J Haematol; 2021 Jan; 192(2):310-321. PubMed ID: 32410217
[TBL] [Abstract][Full Text] [Related]
17. Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.
Sun C; Ye JN; Mao JJ; Ma KW; Zhou X
Oncol Res Treat; 2020; 43(11):592-604. PubMed ID: 33045715
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
19. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
20. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
